@article{3103665,
    title = "Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology",
    author = "Pudil, R. and Mueller, C. and Čelutkienė, J. and Henriksen, P.A. and Lenihan, D. and Dent, S. and Barac, A. and Stanway, S. and Moslehi, J. and Suter, T.M. and Ky, B. and Štěrba, M. and Cardinale, D. and Cohen-Solal, A. and Tocchetti, C.G. and Farmakis, D. and Bergler-Klein, J. and Anker, M.S. and Von Haehling, S. and Belenkov, Y. and Iakobishvili, Z. and Maack, C. and Ciardiello, F. and Ruschitzka, F. and Coats, A.J.S. and Seferovic, P. and Lainscak, M. and Piepoli, M.F. and Chioncel, O. and Bax, J. and Hulot, J.-S. and Skouri, H. and Hägler-Laube, E.S. and Asteggiano, R. and Fernandez, T.L. and de Boer, R.A. and Lyon, A.R.",
    journal = "European Journal of Heart Failure",
    year = "2020",
    volume = "22",
    number = "11",
    pages = "1966-1983",
    publisher = "John Wiley and Sons Ltd",
    doi = "10.1002/ejhf.2017",
    keywords = "amino terminal pro brain natriuretic peptide;  anthracycline;  bevacizumab;  biological marker;  bortezomib;  brain natriuretic peptide;  carfilzomib;  daunorubicin;  doxorubicin;  epirubicin;  idarubicin;  immune checkpoint inhibitor;  ixazomib;  lapatinib;  paclitaxel;  pazopanib;  pertuzumab;  ramucirumab;  sorafenib;  sunitinib;  trastuzumab;  troponin I;  troponin T;  antineoplastic agent;  cardiotonic agent;  tumor marker, Article;  cancer chemotherapy;  cancer patient;  cancer radiotherapy;  cancer therapy;  cardiotoxicity;  chimeric antigen receptor T-cell immunotherapy;  echocardiography;  Europe;  heart failure;  heart left ventricle ejection fraction;  high risk patient;  human;  intermediate risk patient;  low risk patient;  malignant neoplasm;  molecularly targeted therapy;  monitoring;  myocardial disease;  priority journal;  prognosis;  protein blood level;  risk assessment;  treatment response;  blood;  cardiotoxicity;  heart failure;  neoplasm, Antineoplastic Agents;  Biomarkers, Tumor;  Cardiotonic Agents;  Cardiotoxicity;  Heart Failure;  Humans;  Neoplasms",
    abstract = "Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic peptides can be used to guide initiation of cardioprotective treatments for cancer patients during treatment and to monitor the response to cardioprotective treatments, and they also offer prognostic value. This position statement examines the role of cardiac biomarkers in the management of cancer patients. The Cardio-Oncology Study Group of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the Cardio-Oncology Council of the ESC have evaluated the current evidence for the role of cardiovascular biomarkers in cancer patients before, during and after cardiotoxic cancer therapies. The characteristics of the main two biomarkers troponin and natriuretic peptides are discussed, the link to the mechanisms of cardiovascular toxicity, and the evidence for their clinical use in surveillance during and after anthracycline chemotherapy, trastuzumab and HER2-targeted therapies, vascular endothelial growth factor inhibitors, proteasome inhibitors, immune checkpoint inhibitors, cyclophosphamide and radiotherapy. Novel surveillance clinical pathways integrating cardiac biomarkers for cancer patients receiving anthracycline chemotherapy or trastuzumab biomarkers are presented and future direction in cardio-oncology biomarker research is discussed. © 2020 European Society of Cardiology"
}